View Future GrowthFermentalg 過去の業績過去 基準チェック /06Fermentalgの収益は年間平均-12.7%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間4.4% 24.8%割合で 増加しています。主要情報-12.75%収益成長率11.76%EPS成長率Chemicals 業界の成長12.41%収益成長率24.84%株主資本利益率-37.48%ネット・マージン-70.51%次回の業績アップデート16 Jul 2026最近の業績更新お知らせ • Jan 17+ 5 more updatesFermentalg SA to Report Fiscal Year 2025 Final Results on Apr 02, 2026Fermentalg SA announced that they will report fiscal year 2025 final results at 5:40 PM, Central European Standard Time on Apr 02, 2026お知らせ • Jan 15Fermentalg SA to Report Fiscal Year 2024 Results on Mar 20, 2025Fermentalg SA announced that they will report fiscal year 2024 results After-Market on Mar 20, 2025Reported Earnings • Oct 11First half 2024 earnings released: €0.095 loss per share (vs €0.13 loss in 1H 2023)First half 2024 results: €0.095 loss per share (improved from €0.13 loss in 1H 2023). Revenue: €6.32m (up 170% from 1H 2023). Net loss: €5.66m (flat on 1H 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 04Full year 2023 earnings released: €0.32 loss per share (vs €0.24 loss in FY 2022)Full year 2023 results: €0.32 loss per share (further deteriorated from €0.24 loss in FY 2022). Revenue: €5.12m (down 33% from FY 2022). Net loss: €14.1m (loss widened 43% from FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Jan 23+ 4 more updatesFermentalg SA to Report Fiscal Year 2023 Results on Apr 03, 2024Fermentalg SA announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 03, 2024Reported Earnings • Apr 21Full year 2022 earnings released: €0.24 loss per share (vs €0.19 loss in FY 2021)Full year 2022 results: €0.24 loss per share (further deteriorated from €0.19 loss in FY 2021). Revenue: €9.04m (up 60% from FY 2021). Net loss: €9.87m (loss widened 44% from FY 2021). Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Nathalie Vallier was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Breakeven Date Change • May 20Forecast to breakeven in 2028The 3 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2027. The company is expected to make a profit of €400.0k in 2028. Average annual earnings growth of 64% is required to achieve expected profit on schedule.お知らせ • May 15Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million.Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,725,985 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listingお知らせ • May 14Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million.Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,000,000 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listingお知らせ • May 07Fermentalg SA, Annual General Meeting, Jun 11, 2026Fermentalg SA, Annual General Meeting, Jun 11, 2026. Location: 4 rue riviere, libourne Franceお知らせ • Jan 17+ 5 more updatesFermentalg SA to Report Fiscal Year 2025 Final Results on Apr 02, 2026Fermentalg SA announced that they will report fiscal year 2025 final results at 5:40 PM, Central European Standard Time on Apr 02, 2026Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Nathalie Vallier was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 08Fermentalg SA, Annual General Meeting, Jun 12, 2025Fermentalg SA, Annual General Meeting, Jun 12, 2025. Location: 4 rue riviere, libourne Franceお知らせ • Jan 15Fermentalg SA to Report Fiscal Year 2024 Results on Mar 20, 2025Fermentalg SA announced that they will report fiscal year 2024 results After-Market on Mar 20, 2025Reported Earnings • Oct 11First half 2024 earnings released: €0.095 loss per share (vs €0.13 loss in 1H 2023)First half 2024 results: €0.095 loss per share (improved from €0.13 loss in 1H 2023). Revenue: €6.32m (up 170% from 1H 2023). Net loss: €5.66m (flat on 1H 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.New Risk • Jun 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 105% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.3m net loss in 2 years). Revenue is less than US$5m (€4.1m revenue, or US$4.3m). Market cap is less than US$100m (€36.2m market cap, or US$38.8m).お知らせ • May 09Fermentalg SA, Annual General Meeting, Jun 11, 2024Fermentalg SA, Annual General Meeting, Jun 11, 2024. Location: 4 rue riviere, libourne FranceReported Earnings • Apr 04Full year 2023 earnings released: €0.32 loss per share (vs €0.24 loss in FY 2022)Full year 2023 results: €0.32 loss per share (further deteriorated from €0.24 loss in FY 2022). Revenue: €5.12m (down 33% from FY 2022). Net loss: €14.1m (loss widened 43% from FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Jan 23+ 4 more updatesFermentalg SA to Report Fiscal Year 2023 Results on Apr 03, 2024Fermentalg SA announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 03, 2024New Risk • Sep 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$27.3m).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.8m net loss in 2 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€26.7m market cap, or US$29.6m).Board Change • Jul 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helene Moncorger-Pilicer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 21Full year 2022 earnings released: €0.24 loss per share (vs €0.19 loss in FY 2021)Full year 2022 results: €0.24 loss per share (further deteriorated from €0.19 loss in FY 2021). Revenue: €9.04m (up 60% from FY 2021). Net loss: €9.87m (loss widened 44% from FY 2021). Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Feb 15+ 5 more updatesFermentalg SA to Report Fiscal Year 2022 Results on Apr 20, 2023Fermentalg SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Apr 20, 2023Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Oct 04First half 2022 earnings released: €0.13 loss per share (vs €0.17 loss in 1H 2021)First half 2022 results: €0.13 loss per share. Revenue: €5.68m (up 77% from 1H 2021). Net loss: €5.44m (loss widened 14% from 1H 2021). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Germany.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 23Full year 2021 earnings released: €0.19 loss per share (vs €0.32 loss in FY 2020)Full year 2021 results: €0.19 loss per share (up from €0.32 loss in FY 2020). Revenue: €6.80m (up 86% from FY 2020). Net loss: €6.85m (flat on FY 2020). Over the next year, revenue is forecast to grow 45%, compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 23First half 2021 earnings released: €0.17 loss per share (vs €0.23 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: €3.21m (up 67% from 1H 2020). Net loss: €4.76m (loss widened 7.1% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 17Full year 2020 earnings released: €0.32 loss per share (vs €0.97 loss in FY 2019)Full year 2020 results: Net loss: €6.88m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Jan 06New 90-day high: €2.49The company is up 85% from its price of €1.35 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: €1.10The company is down 38% from its price of €1.78 on 30 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 12New 90-day low: €1.28The company is down 6.0% from its price of €1.37 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €16.4m, with losses widening by 62% from the prior year.収支内訳Fermentalg の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:1F6 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 2513-90530 Sep 2513-100530 Jun 2513-120531 Mar 2512-120531 Dec 2411-130530 Sep 2410-140530 Jun 248-140531 Mar 246-140431 Dec 234-140430 Sep 234-120430 Jun 235-100431 Mar 236-100531 Dec 228-100530 Sep 228-90530 Jun 228-80531 Mar 227-70531 Dec 216-70530 Sep 215-70530 Jun 214-70531 Mar 213-70531 Dec 202-70630 Sep 203-12-1530 Jun 203-16-2531 Mar 204-17-1531 Dec 194-171530 Sep 193-143530 Jun 193-105531 Mar 192-95431 Dec 182-84430 Sep 182-84430 Jun 182-83431 Mar 182-73431 Dec 171-73530 Sep 171-83430 Jun 170-84331 Mar 171-84331 Dec 161-84330 Sep 161-64330 Jun 162-55331 Mar 162-54331 Dec 152-54330 Sep 152-54330 Jun 152-533質の高い収益: 1F6は現在利益が出ていません。利益率の向上: 1F6は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 1F6は利益が出ておらず、過去 5 年間で損失は年間12.7%の割合で増加しています。成長の加速: 1F6の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 1F6は利益が出ていないため、過去 1 年間の収益成長をChemicals業界 ( -13.5% ) と比較することは困難です。株主資本利益率高いROE: 1F6は現在利益が出ていないため、自己資本利益率 ( -37.48% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 00:21終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fermentalg SA 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Fanny MeindreCIC Market Solutions (ESN)Guillaume CuvillierGilbert DupontStephanie LefebvreGilbert Dupont5 その他のアナリストを表示
お知らせ • Jan 17+ 5 more updatesFermentalg SA to Report Fiscal Year 2025 Final Results on Apr 02, 2026Fermentalg SA announced that they will report fiscal year 2025 final results at 5:40 PM, Central European Standard Time on Apr 02, 2026
お知らせ • Jan 15Fermentalg SA to Report Fiscal Year 2024 Results on Mar 20, 2025Fermentalg SA announced that they will report fiscal year 2024 results After-Market on Mar 20, 2025
Reported Earnings • Oct 11First half 2024 earnings released: €0.095 loss per share (vs €0.13 loss in 1H 2023)First half 2024 results: €0.095 loss per share (improved from €0.13 loss in 1H 2023). Revenue: €6.32m (up 170% from 1H 2023). Net loss: €5.66m (flat on 1H 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 04Full year 2023 earnings released: €0.32 loss per share (vs €0.24 loss in FY 2022)Full year 2023 results: €0.32 loss per share (further deteriorated from €0.24 loss in FY 2022). Revenue: €5.12m (down 33% from FY 2022). Net loss: €14.1m (loss widened 43% from FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Jan 23+ 4 more updatesFermentalg SA to Report Fiscal Year 2023 Results on Apr 03, 2024Fermentalg SA announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 03, 2024
Reported Earnings • Apr 21Full year 2022 earnings released: €0.24 loss per share (vs €0.19 loss in FY 2021)Full year 2022 results: €0.24 loss per share (further deteriorated from €0.19 loss in FY 2021). Revenue: €9.04m (up 60% from FY 2021). Net loss: €9.87m (loss widened 44% from FY 2021). Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Nathalie Vallier was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • May 20Forecast to breakeven in 2028The 3 analysts covering Fermentalg expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 36% per year to 2027. The company is expected to make a profit of €400.0k in 2028. Average annual earnings growth of 64% is required to achieve expected profit on schedule.
お知らせ • May 15Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million.Fermentalg SA has completed a Follow-on Equity Offering in the amount of €10.913953 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,725,985 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listing
お知らせ • May 14Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million.Fermentalg SA has filed a Follow-on Equity Offering in the amount of €16.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,000,000 Price\Range: €0.46 Transaction Features: Regulation S; Rule 144A; Subsequent Direct Listing
お知らせ • May 07Fermentalg SA, Annual General Meeting, Jun 11, 2026Fermentalg SA, Annual General Meeting, Jun 11, 2026. Location: 4 rue riviere, libourne France
お知らせ • Jan 17+ 5 more updatesFermentalg SA to Report Fiscal Year 2025 Final Results on Apr 02, 2026Fermentalg SA announced that they will report fiscal year 2025 final results at 5:40 PM, Central European Standard Time on Apr 02, 2026
Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Nathalie Vallier was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 08Fermentalg SA, Annual General Meeting, Jun 12, 2025Fermentalg SA, Annual General Meeting, Jun 12, 2025. Location: 4 rue riviere, libourne France
お知らせ • Jan 15Fermentalg SA to Report Fiscal Year 2024 Results on Mar 20, 2025Fermentalg SA announced that they will report fiscal year 2024 results After-Market on Mar 20, 2025
Reported Earnings • Oct 11First half 2024 earnings released: €0.095 loss per share (vs €0.13 loss in 1H 2023)First half 2024 results: €0.095 loss per share (improved from €0.13 loss in 1H 2023). Revenue: €6.32m (up 170% from 1H 2023). Net loss: €5.66m (flat on 1H 2023). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
New Risk • Jun 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 105% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.3m net loss in 2 years). Revenue is less than US$5m (€4.1m revenue, or US$4.3m). Market cap is less than US$100m (€36.2m market cap, or US$38.8m).
お知らせ • May 09Fermentalg SA, Annual General Meeting, Jun 11, 2024Fermentalg SA, Annual General Meeting, Jun 11, 2024. Location: 4 rue riviere, libourne France
Reported Earnings • Apr 04Full year 2023 earnings released: €0.32 loss per share (vs €0.24 loss in FY 2022)Full year 2023 results: €0.32 loss per share (further deteriorated from €0.24 loss in FY 2022). Revenue: €5.12m (down 33% from FY 2022). Net loss: €14.1m (loss widened 43% from FY 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Jan 23+ 4 more updatesFermentalg SA to Report Fiscal Year 2023 Results on Apr 03, 2024Fermentalg SA announced that they will report fiscal year 2023 results at 5:40 PM, Central European Standard Time on Apr 03, 2024
New Risk • Sep 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$27.3m).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.8m net loss in 2 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.2% increase in shares outstanding). Market cap is less than US$100m (€26.7m market cap, or US$29.6m).
Board Change • Jul 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helene Moncorger-Pilicer was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 21Full year 2022 earnings released: €0.24 loss per share (vs €0.19 loss in FY 2021)Full year 2022 results: €0.24 loss per share (further deteriorated from €0.19 loss in FY 2021). Revenue: €9.04m (up 60% from FY 2021). Net loss: €9.87m (loss widened 44% from FY 2021). Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Feb 15+ 5 more updatesFermentalg SA to Report Fiscal Year 2022 Results on Apr 20, 2023Fermentalg SA announced that they will report fiscal year 2022 results at 9:00 AM, Central European Standard Time on Apr 20, 2023
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Oct 04First half 2022 earnings released: €0.13 loss per share (vs €0.17 loss in 1H 2021)First half 2022 results: €0.13 loss per share. Revenue: €5.68m (up 77% from 1H 2021). Net loss: €5.44m (loss widened 14% from 1H 2021). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Germany.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 23Full year 2021 earnings released: €0.19 loss per share (vs €0.32 loss in FY 2020)Full year 2021 results: €0.19 loss per share (up from €0.32 loss in FY 2020). Revenue: €6.80m (up 86% from FY 2020). Net loss: €6.85m (flat on FY 2020). Over the next year, revenue is forecast to grow 45%, compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. Independent Director Helene Moncorger-Pilicer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 23First half 2021 earnings released: €0.17 loss per share (vs €0.23 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: €3.21m (up 67% from 1H 2020). Net loss: €4.76m (loss widened 7.1% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 17Full year 2020 earnings released: €0.32 loss per share (vs €0.97 loss in FY 2019)Full year 2020 results: Net loss: €6.88m (loss narrowed 60% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Jan 06New 90-day high: €2.49The company is up 85% from its price of €1.35 on 08 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: €1.10The company is down 38% from its price of €1.78 on 30 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 12New 90-day low: €1.28The company is down 6.0% from its price of €1.37 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Reported Earnings • Sep 18First half earnings releasedOver the last 12 months the company has reported total losses of €16.4m, with losses widening by 62% from the prior year.